On Monday, Biomarin Pharmaceutical Inc (BMRN) stock saw a decline, ending the day at $66.01 which represents a decrease of $-0.59 or -0.89% from the prior close of $66.6. The stock opened at $66.24 ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of BioMarin Pharmaceutical (BMRN) and Incyte (INCY). But which of these two companies is ...

BioMarin Pharmaceutical (BMRN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by ...

On Tuesday, Biomarin Pharmaceutical Inc (BMRN) stock saw a decline, ending the day at $69.91 which represents a decrease of $-0.22 or -0.31% from the prior close of $70.13. The stock opened at $69.78 ...

BioMarin posts Q3 EPS of $0.91, nearly doubling last year's $0.46 and topping estimates. Sales rose 28%, driven by strong ...

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at three upcoming investor conferences.

Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on BMRN stock, giving a Buy rating today. Joseph Schwartz has ...

BioMarin Pharmaceutical (BMRN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

A total of 27 analyst ratings have been received for Biomarin Pharmaceutical, with the consensus rating being Outperform. The average one-year price target stands at $100.85, suggesting a potential 44 ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Get Free Report)’s stock price reached a new 52-week low during trading on Wednesday following a weaker than expected earnings announcement. The stock ...